

**MOLECULAR STUDIES ON *HOXD* GENES:
NEW INSIGHTS INTO THE MECHANISMS OF LIMB
DEVELOPMENT AND PATHOGENESIS.**

**Dissertation zur Erlangung des akademischen Grades des
Doktors der Naturwissenschaften (Dr. rer. nat.)**

**eingereicht im Fachbereich Biologie, Chemie, Pharmazie
der Freien Universität Berlin**

vorgelegt von

BARBARA DŁUGASZEWSKA

aus Poznań, Polen

September 2005

1. Gutachter: Prof. Dr. Stefan Mundlos

2. Gutachter: Prof. Dr. Horst Kreß

Disputation am 5. Dezember 2005

TABLE OF CONTENTS

ABBREVIATIONS.....	6
1 INTRODUCTION.....	8
1.1 Origin of tetrapod limbs.....	8
1.2 Limb development in embryogenesis.....	8
1.2.1 Anatomical view.....	8
1.2.2 Molecular basis of limb patterning.....	9
1.2.2.1 Establishment of the proximodistal axis in the limb.....	9
1.2.2.2 Establishment of the AP axis.....	10
1.2.2.3 Limb patterning along the dorsoventral axis.....	11
1.3 <i>HOX</i> genes in limb development.....	12
1.3.1 Chromosomal clustering of <i>Hox</i> genes is linked to a specific expression pattern during embryogenesis.....	12
1.3.2 <i>Hox</i> genes and pre-patterning of the embryo.....	13
1.3.3 Posterior <i>Hoxa</i> and <i>Hoxd</i> genes and their role in limb patterning.....	13
1.3.4 A special role of the posterior <i>Hoxd</i> genes in the development of digitated limbs and the contribution of different pathways to digit formation.....	15
1.3.5 Mechanisms controlling expression of <i>Hox</i> genes.....	16
1.3.5.1 Regulation of single <i>Hox</i> genes.....	16
1.3.5.2 Global regulation of the <i>Hox</i> clusters.....	17
1.3.5.3 Regulation of the posterior <i>Hox</i> genes during limb development.....	18
1.3.6 <i>HOX</i> gene mutations and limb malformations in humans.....	19
1.3.7 <i>Hox</i> proteins in complexes.....	20
1.4 Outline of the project.....	21
2 MATERIALS AND METHODS.....	23
2.1 Materials.....	23
2.1.1 Chemicals and reagents.....	23
2.1.2 Buffers and solutions.....	26
2.1.3 Media.....	31
2.1.3.1 Yeast media.....	31

2.1.3.2	Bacterial media.....	33
2.1.3.3	Cell culture media.....	33
2.1.4	Enzymes.....	34
2.1.5	Kits.....	34
2.1.6	Vectors and universal primers.....	35
2.1.7	Antibodies.....	36
2.1.8	Primers.....	37
2.1.9	Genomic clones, ESTs and genomic and cDNA libraries.....	37
2.1.10	Bacteria.....	37
2.1.11	Yeast.....	37
2.1.12	Mammalian cell lines.....	37
2.1.13	Mouse embryos.....	37
2.2	Methods.....	38
2.2.1	DNA isolation.....	38
2.2.2	Fluorescence <i>in situ</i> hybridisation (FISH).....	38
2.2.3	Amplification of DNA probes for Southern blot hybridisation.....	39
2.2.4	Isotope-labelling of probes for Southern blot hybridisation.....	39
2.2.5	Southern blot hybridisation.....	40
2.2.6	Genomic walking.....	40
2.2.7	Screening for mutations in the <i>HOXD13</i> gene in the translocation patient.....	41
2.2.8	RNA isolation.....	43
2.2.9	Analysis of <i>MGMT</i> expression by Northern blot.....	43
2.2.10	RT-PCR analysis.....	44
2.2.11	Construction of yeast and mammalian expression vectors.....	48
2.2.11.1	<i>Hoxd13</i> cloning.....	48
2.2.11.2	<i>Peg10</i> cloning.....	49
2.2.11.3	Cloning of other candidate genes identified in the yeast two-hybrid screen.....	51
2.2.12	Small scale yeast transformation.....	51
2.2.13	Preparation of yeast protein extracts.....	52
2.2.14	Yeast two-hybrid screen.....	52
2.2.15	LacZ colony filter assay.....	53
2.2.16	Analysis of prey inserts in double positive yeast clones.....	54
2.2.17	Preparation of chemical competent <i>E. coli</i> cells.....	54

2.2.18	Isolation of prey plasmids from double positive yeast colonies.....	55
2.2.19	Confirmation of protein-protein interactions in yeast.....	55
2.2.20	Cell culture and DNA transfection.....	56
2.2.21	Immunocytochemistry.....	56
2.2.22	Coimmunoprecipitation.....	57
2.2.23	SDS-PAGE and Western blot analysis.....	57
2.2.24	Synthesis of RNA probes for <i>in situ</i> hybridisation.....	58
2.2.25	Whole mount <i>in situ</i> hybridisation.....	59
2.2.26	Section <i>in situ</i> hybridisation.....	60
3	RESULTS.....	62
3.1	Analysis of a balanced translocation t(2;10)(q31.1;q26.3) in a male patient with SPD.....	62
3.1.1	Clinical description of the male patient with a <i>de novo</i> balanced translocation t(2;10)(q31.1;q26.3).....	62
3.1.2	Cytogenetic investigation of the chromosomal breakpoints in the patient.....	63
3.1.3	Southern blot experiments and cloning of the breakpoints.....	65
3.1.4	The <i>MGMT</i> gene is disrupted by the breakpoint but it is still expressed from the intact chromosome 10 in the translocation patient.....	67
3.1.5	Analysis of the breakpoint region on chromosome 2.....	69
3.1.5.1	The breakpoint on chromosome 2 does not disrupt any known gene.....	69
3.1.5.2	The <i>HOXD13</i> gene is not mutated in the patient.....	70
3.1.5.3	The human sequence upstream to the breakpoint shows high homology to the corresponding region in mouse.....	70
3.2	Screening for Hoxd13 interaction partners.....	72
3.2.1	Yeast two-hybrid screen as a commonly used method to identify protein-protein interactions.....	72
3.2.2	Construction of the bait vector.....	73
3.2.3	Yeast two-hybrid screen.....	75
3.2.4	Analysis of positive colonies.....	77
3.2.5	Peg10 as a putative Hoxd13 interaction partner.....	79
3.2.5.1	Confirmation of the interaction with Hoxd13-HD in LexA and GAL4 systems.....	81
3.2.5.2	Cloning of <i>Peg10</i>	82
3.2.5.3	Immunocytochemistry studies.....	83
3.2.5.4	Coimmunoprecipitation assay.....	85
3.2.5.5	Whole-mount and section <i>in situ</i> hybridisation.....	86
3.2.6	Investigation of other putative Hoxd13 binding proteins.....	88
3.2.6.1	Studies on Dlxin-1.....	88
3.2.6.2	LIM domain-containing genes.....	89

3.6.2.3	Cnot3 as a putative Hoxd13 binding partner.....	93
4	DISCUSSION.....	94
4.1	Genotype-phenotype correlation in the patient with a translocation t(2;10)(q31.1;q26.3).....	94
4.1.1	The <i>MGMT</i> gene on chromosome 10 disrupted by the breakpoint does not seem to be responsible for the limb phenotype of the patient.....	94
4.1.2	Could the disruption of <i>MGMT</i> have influenced the mental status of the patient?.....	95
4.1.3	There is no evidence for any gene disrupted on chromosome 2 in the patient with the translocation t(2;10)(q31.1;q26.3)	95
4.1.4	<i>HOXD</i> genes located close to the breakpoint on chromosome 2 are good candidates for the limb phenotype in the patient.....	96
4.1.5	Chromosomal rearrangements can cause disorders in humans and mice via position effect.....	96
4.1.5.1	Mechanisms leading to a position effect.....	97
4.1.5.2	<i>HOXD</i> gene expression may be influenced by the accessibility of the entire cluster for transcription factors.....	99
4.1.6	Are others genes possibly involved in the patient's phenotype?	100
4.2	Search for interaction partners of Hoxd13 protein.....	100
4.2.1	Peg10 is a putative Hoxd13 binding protein.....	101
4.2.1.1	Parts of the Peg10 protein bind Hoxd13-HD in yeast.....	101
4.2.1.2	Interaction between Peg10 and Hoxd13 in mammalian cells.....	101
4.2.1.3	Does Peg10 bind Hoxd13 <i>in vivo</i> ?	102
4.2.1.4	A putative role of Peg10 proteins and Hoxd13/Peg10 complexes in limb development.....	103
4.2.1.5	Ala-stretch mutations within Hoxd13 do not influence the binding to Peg10.....	104
4.2.2	Other potential Hoxd13 interaction partners.....	105
4.2.3	Outlook.....	106
5	SUMMARY.....	107
6	ZUSAMMENFASSUNG.....	109
7	ELECTRONIC DATABASE INFORMATION.....	111
8	REFERENCES.....	112
9	ACKNOWLEDGEMENTS.....	131
10	PUBLICATIONS.....	132

11 APPENDICES.....	133
11.1 Vector pVP16.....	133
11.2 Vector pBTM116.....	134
11.3 Vector pcDNA-Flag.....	135
11.4 Vector pTL1-HA2.....	136
11.5 List of putative ESTs found on BAC RP11-538A12.....	137
11.6 List of putative non-coding high homology regions (HHR) found after human-mouse sequence comparison.....	138
11.7 Alignment of <i>Peg10</i> and <i>Edr</i> nucleotide sequences.....	139